SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies soars on getting nod under PLI scheme for manufacturer pharmaceutical goods

09 Dec 2021 Evaluate

Venus Remedies is currently trading at Rs. 508.45, up by 38.40 points or 8.17% from its previous closing of Rs. 470.05 on the BSE.

The scrip opened at Rs. 491.00 and has touched a high and low of Rs. 531.00 and Rs. 491.00 respectively. So far 23533 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 638.50 on 09-Aug-2021 and a 52 week low of Rs. 116.85 on 22-Dec-2020.

Last one week high and low of the scrip stood at Rs. 531.00 and Rs. 436.10 respectively. The current market cap of the company is Rs. 673.50 crore.

The promoters holding in the company stood at 40.81%, while Institutions and Non-Institutions held 0.10% and 59.09% respectively.

Venus Remedies has received approval from the Government of India under PLI 2.0 of the Production Linked Incentive (PLI) Scheme for manufacturers of pharmaceutical goods registered in India. Venus is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the PLI Scheme. As per the scheme, the Company will be eligible for incentive for the financial years 2022-23 to 2027-28, subject to fulfillment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×